0000000000274712

AUTHOR

Shah S

showing 7 related works from this author

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

2015

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular deat…

Oralmedicine.medical_specialtyHeart diseasesGlycosylatedAdministration Oralheart failureType 2 diabetesDipeptidyl peptidase-4 inhibitorKaplan-Meier EstimatePlaceboSitagliptin PhosphateSitagliptin Cardiovascular Outcomeschemistry.chemical_compoundDrug TherapyDouble-Blind MethodInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentsGlycated HemoglobinHemoglobin A GlycosylatedAdministration Oral; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Drug Therapy Combination; Follow-Up Studies; Heart Diseases; Heart Failure; Hemoglobin A Glycosylated; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles; Medicine (all)business.industryMedicine (all)SemaglutideSitagliptin PhosphateHemoglobin AGeneral MedicineTriazolesta3121medicine.diseaseSurgeryHospitalizationCardiovascular diseaseschemistryDiabetes Mellitus Type 2SitagliptinPyrazinesAdministrationCombinationDrug Therapy CombinationGlycated hemoglobinbusinessType 2Alogliptinmedicine.drugFollow-Up StudiesNew England Journal of Medicine
researchProduct

Software Startups – A Research Agenda

2016

Software startup companies develop innovative, software-intensive products within limited timeframes and with few resources, searching for sustainable and scalable business models. Softwarestartups are quite distinct from traditional mature software companies, but also from micro-,small-, and medium-sized enterprises, introducing new challenges relevant for software engineeringresearch. This paper’s research agenda focuses on software engineering in startups, identifying,in particular, 70+ research questions in the areas of supporting startup engineering activities,startup evolution models and patterns, ecosystems and innovation hubs, human aspects in softwarestartups, applying startup conc…

lcsh:Computer softwareProgramvaruteknik05 social sciencesresearch agendaSoftware startupsCIÊNCIA DA COMPUTAÇÃOSoftware Engineering020207 software engineering02 engineering and technologysoftware startuplcsh:QA76.75-76.7650502 economics and business0202 electrical engineering electronic engineering information engineeringsoftware-intensive systems050203 business & management
researchProduct

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

2012

Albinterferon alfa-2b (albIFN) is a fusion protein of recombinant human albumin/recombinant interferon (IFN)-α-2b, with ∼200-h half-life. Safety/efficacy of albIFN q4wk was evaluated in 391 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 2/3. Patients were randomized 3:4:4:4 to one of four open-label treatment groups: pegylated IFN (Peg-IFN)-α-2a 180 μg qwk or albIFN 900, 1200 or 1500 μg q4wk, plus oral ribavirin 800 mg/day, for 24 weeks. Primary efficacy endpoint was sustained virologic response (SVR; HCV RNA <20 IU/mL 24 weeks post-treatment). SVR rates were as follows: 85%, 76%, 76% and 78% with Peg-IFNα-2a and albIFN 900, 1200 and 1500 μg, respectively (P = NS); c…

AdultMaleANTIVIRAL TREATMENTGenotypeInterleukinsInterferon-alphaHepacivirusHepatitis C ChronicMiddle AgedViral LoadAntiviral AgentsAlbinterferon alfa-2bTreatment OutcomeAlbuminsHumansRNA ViralFemaleInterferonshepatitis CAlbinterferon alfa-2b; hepatitis c; ANTIVIRAL TREATMENT
researchProduct

Body mass index and complications following major gastrointestinal surgery

2018

Aim Previous studies reported conflicting evidence on the effects of obesity on outcomes after gastrointestinal surgery. The aims of this study were to explore the relationship of obesity with major postoperative complications in an international cohort and to present a meta-analysis of all available prospective data.Methods This prospective, multicentre study included adults undergoing both elective and emergency gastrointestinal resection, reversal of stoma or formation of stoma. The primary end-point was 30-day major complications (Clavien-Dindo Grades III-V). A systematic search was undertaken for studies assessing the relationship between obesity and major complications after gastroint…

MaleobesityMultivariate analysisGastrointestinal DiseasesIMPACTSettore MED/18 - CHIRURGIA GENERALEBody mass index; Body weight; Digestive tract; Gastrointestinal tract; Obesity; Postoperative complications; Gastroenterologydigestive tractTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicineGastrointestinal tractRisk FactorsMedicineProspective StudiesProspective cohort studyBody mass indexBody mass index; Body weight; Digestive tract; Gastrointestinal tract; Obesity; Postoperative complications; Aged; Europe; Female; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Obesity; Postoperative Complications; Prospective Studies; Risk Factors; Body Mass IndexGastrointestinal NeoplasmsOUTCOMESPostoperative complications; body mass index; body weight; digestive tract; gastrointestinal tract; obesityGastroenterologyMiddle AgedBody mass index; Body weight; Digestive tract; Gastrointestinal tract; Obesity; Postoperative complicationsEurope030220 oncology & carcinogenesisMeta-analysisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]CohortFemale030211 gastroenterology & hepatologyCohort studymedicine.medical_specialtybody mass indexMalignancyNO03 medical and health sciencesPostoperative complicationsbody weightSDG 3 - Good Health and Well-beingHumansDigestive tractObesityAgedbusiness.industrypostoperative complications; obesity; digestive tract; gastrointestinal tract; body mass index; body weightMORTALITYBody weightmedicine.diseaseObesitySettore MED/18SurgeryPostoperative complicationPostoperative Complications Obesity Digestive Tract Gastrointestinal Tract Body Mass Index Body Weight.gastrointestinal tractbusinessBody mass indexColorectal Disease
researchProduct

An international perspective on hospitalized patients with viral community-acquired pneumonia

2019

Background Who should be tested for viruses in patients with community acquired pneumonia (CAP), prevalence and risk factors for viral CAP are still debated. We evaluated the frequency of viral testing, virus prevalence, risk factors and treatment coverage with oseltamivir in patients admitted for CAP. Methods Secondary analysis of GLIMP, an international, multicenter, point-prevalence study of hospitalized adults with CAP. Testing frequency, prevalence of viral CAP and treatment with oseltamivir were assessed among patients who underwent a viral swab. Univariate and multivariate analysis was used to evaluate risk factors. Results 553 (14.9%) patients with CAP underwent nasal swab. Viral CA…

PNEUMONIAMaleMultivariate analysisInternationalityPCV13 pneumococcal conjugate vaccineDatabases FactualHospitalized patientsmedicine.medical_treatmentvirusesCAD coronary artery diseaseTesting030204 cardiovascular system & hematologyMRSA methicillin resistant Staphylococcus aureusPneumònia adquirida a la comunitatRT-PCR reverse transcriptase polymerase chain reactionchemistry.chemical_compound0302 clinical medicineCommunity-acquired pneumoniaTaverne80 and overCommunity-Acquired InfectionViral030212 general & internal medicineProspective StudiesAged 80 and overRIDT rapid influenza diagnostic testCAP community-acquired pneumoniaRSV Respiratory Syncytial virusMiddle AgedICU intensive care unitCommunity-Acquired InfectionsHospitalizationNasal SwabInfectious diseasesFemaleViral swabHumanOseltamivirmedicine.medical_specialtyLogistic ModelCommunity-acquired pneumoniaViral pneumoniaCommunity acquired pneumonia; Influenza; Oseltamivir; Testing; Viral pneumonia; Viral swab; Aged; Aged 80 and over; Antiviral Agents; Community-Acquired Infections; Cross-Sectional Studies; Databases Factual; Female; Hospitalization; Humans; Influenza Human; Internationality; Logistic Models; Male; Medication Adherence; Middle Aged; Oseltamivir; Pneumonia Viral; Prospective StudiesPneumonia ViralAdmissionSettore MED/10 - Malattie Dell'Apparato RespiratorioInfluenzavirusAntiviral AgentsVirusArticleMedication AdherenceHMPV human MetapneumovirusDatabases03 medical and health sciencesLRTI lower respiratory tract infectionOseltamivirInternal medicineInfluenza HumanInternal MedicinemedicineInfluenza virusesHumansHIV Human Immunodeficiency virusPPSV23 pneumococcal polysaccharide vaccineIn patientFactualAgedMechanical ventilationAntiviral AgentCross-Sectional Studiebusiness.industryFEV1 forced expiratory volume in one secondGLIMP global initiative for methicillin-resistant Staphylococcus aureus pneumoniaESBL extended-spectrum beta-lactamasesPneumoniamedicine.diseaseInfluenzaCommunity acquired pneumoniaCI confidence intervalOR odds ratioCross-Sectional StudiesLogistic ModelschemistryCOPD chronic obstructive pulmonary diseasebusinessCommunity acquired pneumonia ; Influenza ; Oseltamivir ; Testing ; Viral pneumonia ; Viral swab
researchProduct

Liraglutide and Renal Outcomes in Type 2 Diabetes.

2017

BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a co…

MaleSettore MED/09 - Medicina InternaAcute Kidney Injury; Aged; Albuminuria; Creatinine; Diabetes Mellitus Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kidney Failure Chronic; Liraglutide; Male; Middle AgedType 2 diabetes030204 cardiovascular system & hematologyurologic and male genital diseasesGLOMERULAR-FILTRATION-RATEKIDNEY-FUNCTIONDISEASElaw.inventionKidney Failurechemistry.chemical_compound0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawMedicineDiabetic NephropathiesHypoglycemic Agents.Settore MED/49 - Scienze Tecniche Dietetiche ApplicateChronicRISKKidneyAcute kidney injury11 Medical And Health SciencesGeneral MedicineAcute Kidney InjuryMiddle AgedIntention to Treat Analysismedicine.anatomical_structureCreatinineTRIALFemaleliraglutide randomized controlled trial type 2 diabetes renal outcomesLife Sciences & BiomedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyRenal function030209 endocrinology & metabolismCARDIOVASCULAR OUTCOMESFollow-Up Studie03 medical and health sciencesMedicine General & InternalDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicineDiabetes MellitusAlbuminuriaHumansHypoglycemic AgentsIntensive care medicineAgedCreatinineScience & Technologybusiness.industryLiraglutideMORTALITYLiraglutidemedicine.diseaseINTENSIVE GLUCOSE CONTROLINDIVIDUALSDiabetes Mellitus Type 2chemistryDiabetic NephropathieKidney Failure ChronicLEADER Steering Committee and InvestigatorsbusinessFollow-Up Studies
researchProduct

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are creat…

2009

Contains fulltext : 80963.pdf (Publisher’s version ) (Open Access) BACKGROUND: The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy. METHODS: We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretrovir…

MaleInfectious diseases and international health [NCEBP 13]Lymphoma030312 virologyEsophageal candidiasisCohort Studies0302 clinical medicineInterquartile range030212 general & internal medicineAIDS-RelatedLymphoma AIDS-Related0303 health sciencesMortality rateProgressive multifocal leukoencephalopathyHazard ratioPrognosis3. Good healthPathogenesis and modulation of inflammation [N4i 1]Infectious DiseasesCombinationDrug Therapy CombinationFemaleInfection and autoimmunity [NCMLS 1]HumanMicrobiology (medical)Adultmedicine.medical_specialtyPrognosiAnti-HIV Agentsantiretroviral therapyInfectious DiseaseArticleAIDS-Related Opportunistic Infection03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)Drug TherapyInternal medicinemedicineHumansAIDS-defining eventProportional Hazards ModelsAIDS-Related Opportunistic Infections/diagnosis/ mortality; Acquired Immunodeficiency Syndrome/complications/diagnosis/drug; therapy/ mortality; Adult; Anti-HIV Agents/ therapeutic use; Cohort Studies; Drug Therapy; Combination; Female; Humans; Lymphoma; AIDS-Related/diagnosis/mortality; Male; Prognosis; Proportional Hazards ModelsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic Infectionsbusiness.industryProportional hazards modelPoverty-related infectious diseases [N4i 3]Anti-HIV Agentmedicine.diseasemortalityConfidence intervalImmunologyProportional Hazards ModelCohort Studiebusiness
researchProduct